Monday, April 25th, 2016 - ReportsnReports adds Global Endocrinology Drugs Market 2016-2020 latest research report, the analysts forecast global endocrinology drugs market to grow at a CAGR of 6.69% during the period 2016-2020. As vendors are facing the problem of a decline in venture capital investment, they are increasingly following the strategy of outsourcing. Different parts of research such as product characterization testing and toxicology testing are outsourced to third-party research organizations. Similarly, some vendors outsource the pharmaceutical product manufacturing or the entire manufacturing process to contract manufacturing organizations. This reduces the operational costs, as most companies do not have to maintain expensive R&D laboratories and scientists. Pharmaceutical companies rely on the contract manufacturing organizations based in India, China, Russia, and Eastern Europe to manufacture and process their products.

Complete report on Endocrinology Drugs market is now available at

According to the endocrinology drugs market report, the increase or decrease in the release of endocrine hormones leads to disorders such as diabetes, hypogonadism, hypothyroidism, and hyperthyroidism. The prevalence of diabetes is rising because of obesity, unhealthy diet, and lack of physical activity among individuals. The prevalence of hypogonadism also increases in men with diabetes, human immunodeficiency virus (HIV), chronic obstructive pulmonary disease, heart or renal disease, or in individuals who are on opiate or glucocorticoid therapy. Thus, the increase in the prevalence of these diseases will lead to the increase in the intake of medications, propelling the market growth.

Segmentation by application and analysis of the endocrinology drugs market

Thyroid hormone disorder drugs

Diabetes drugs

Human growth hormone

Testosterone replacement therapy

During 2015, the diabetes drugs segment dominated the endocrinology drugs market and accounted for more than 86% of the market share. The analysts have estimated factors such as the increasing number of individuals with diabetes and stringent guidelines for biosimilar drugs will propel this segment’s growth over the forecast period. Moreover, rising R&D activities and awareness programs will also significantly contribute to the growth of this segment until the end of 2020.

Order a copy of Global Endocrinology Drugs Market 2016-2020 report @

During 2015, the Americas dominated the global endocrinology market and accounted for more than 58% of the market share in terms of revenue. The US was the largest revenue contributor to the region due to of the increasing prevalence of endocrine diseases like diabetes, thyroid disorders, and hypogonadism. Moreover, the high per capita income and well-developed research facilities will also aid in the growth of this market in the Americas.

The global endocrinology drugs market is highly competitive owing to the presence of several small and large vendors. The market is open to new players and has a lot of opportunities for growth.  The competitive environment is expected to increase in due to the product extensions, new products, and new applications of the products and services provided. 

key players in the Global Endocrinology Drugs Market: AbbVie Inc., AstraZeneca PLC, Eli Lilly and Co., Merck & Co, Novo Nordisk AS, and Sanofi SA.

Other Prominent Vendors in the market are: Acerus Pharmaceuticals, Acrux DDS, Adocia, Æterna Zentaris, Akros Pharma, Allergan, Amgen, Antares Pharma, Ascendis Pharma, Astellas Pharma, Baxalta, Bayer HealthCare Pharmaceuticals, BHV Pharma, Biocon, Biodel, Boehringer Ingelheim, ChipScreen Biosciences, Clarus Therapeutics, ConjuChem, Critical Pharmaceuticals, CureDm, CymaBay Therapeutics, Daiichi Sankyo, Dance Biopharm, DiaMedica, Diamyd Therapeutics, Diasome Pharmaceuticals, DiaVacs, Dong-A ST, Eisai, Elcelyx Therapeutics, Endo Pharmaceuticals, Exsulin, Ferring Pharmaceuticals, Gan & Lee Pharmaceuticals, Genentech, Generex, Genexine, Genfit, GSK, HanAll BioPharma, Hanmi Pharmaceutical, Hua Medicine, ILTOO Pharma, Intarcia Therapeutics, InteKrin Therapeutics, Intrexon, Ionis Pharmaceuticals, Ipe, Islet Sciences, Janssen Pharmaceuticals, Japan Tobacco, Juniper Pharmaceuticals, Kadmon Corporation, Kamada, KinDex Pharmaceuticals, Kissei Pharmaceutical, Kotobuki, Lexicon Pharmaceuticals, LG Life Sciences, Ligand Pharmaceuticals, Lipocine, Living Cell Technologies, MacroGenics, MannKind, MedImmune, Melior Pharmaceuticals, Metabolic Solutions Development Company, MetP Pharma, Mitsubishi Tanabe Pharma, Mylan, NGM Biopharmaceuticals, Novartis, NuSirt Biopharma, OPKO Biologics, Oramed Pharmaceuticals, Osiris Therapeutics, Peptron, Perle Biosciences, Pfizer, PhaseBio Pharmaceuticals, Poxel, ProStrakan Group, REGiMMUNE, Repros Therapeutics, Roche, Sanwa Kagaku Kenkyusho, Sirona Biochem, Strongbridge Biopharma, Takeda Pharmaceuticals, TesoRx Pharma, Teva Pharmaceutical, Theracos, Theratechnologies, Toleranzia, Tolerion, Transition Therapeutics, VeroScience, Versartis, vTv Therapeutics, XBiotech, Xeris Pharmaceuticals, and XOMA.

Inquire for Discount @

File Library

Contact Profile

ReportsnReports is your single source for all market research needs. Our database includes 500,000+ market research reports from over 95 leading global publishers & in-depth market research studies of over 5000 micro markets. With comprehensive information about the publishers and the industries for which they publish market research reports, we help you in your purchase decision by mapping your information needs with our huge collection of reports.

Connect With Us on:  



Twitter: https: //

G+ / Google Plus:



Ritesh Tiwari
P: + 1 888 391 5441


Endocrinology Drugs Market to Grow at 6.69% CAGR Driven by Increase in Prevalence of Endocrine Hormone-Related Diseases to 2020




More Formats